FindTrial
Sign In

AGS-16C3F

DRUG2 trials

Sponsors

Agensys, Inc., Astellas Pharma Global Development, Inc.

Conditions

Carcinoma, Renal CellMetastatic Renal Cell CarcinomaRenal Cell Carcinoma With Clear Cell HistologyRenal Cell Carcinoma With Non-Clear Cell HistologyRenal Cell Carcinoma of Papillary Histology

Phase 1

A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
CompletedNCT01672775
Agensys, Inc.Carcinoma, Renal Cell, Renal Cell Carcinoma of Papillary Histology, Renal Cell Carcinoma With Clear Cell Histology +1
Start: 2012-07-18End: 2017-02-21Updated: 2024-11-01

Phase 2

A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
CompletedNCT02639182
Astellas Pharma Global Development, Inc.Metastatic Renal Cell Carcinoma
Start: 2016-05-03End: 2020-10-02Updated: 2024-11-18

Related Papers

A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma
The Oncologist2020-12-0941 citations
Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RRCC).
Journal of Clinical Oncology2015-05-2025 citations